Skip to main content

The Globe and Mail

Valeant Pharmaceuticals Intl (VRX-N) Quote

Unchecking box will stop auto data updates
Cboe BZX Real-Time Last Sale USD
Today's Change
Volume
Price Quote as of

Today's Trading

Day Low 16.98
Day High 17.39
Open:17.24
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Trailing Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.

More stories below advertisement

Description
Valeant Pharmaceuticals International, Inc. is a pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology, dermatology and branded generics. The Company produces medicines that meet the special health problems of patients. Valeant's development pipeline strategy comprises both new compounds as well as product life cycle management. Its early and late-stage drug candidates have unique formulations and mechanisms of action including retigabine for the treatment of epilepsy and pain, taribavirin of the treatment of chronic hepatitis C, and several dermatology candidates for the treatment of rosacea, acne, and dermatological fungus. Valeant Pharmaceuticals International, Inc. is headquartered in Mississauga, Canada.

Fundamentals

Market Capitalization, $M
Shares Outstanding, M
36-Month Beta
Earnings Per Share (TTM)
1-Year Total Return
3-Year Total Return
5-Year Total Return
Price/Earnings (TTM)
Price/Earnings (Forward)
Trailing Annual Dividend & Yield
Forward Annual Dividend & Yield
Most Recent Dividend
Ex-Div Date
Price/Book
Most Recent Split

Earnings

Corporate earnings are provided from Zacks Investment Research, including Income Statements, Balance Sheets, Cash Flow Statements, and Statement of Retained Earnings.

Analyst Research

Analyst Ratings and Earnings Estimates are provided by Zacks Investment Research – including Buy/Hold Recommendations, Earnings Surprises, Estimates and Recommendations History.

Stock Reports +

Download a comprehensive report detailing quantitative analytics of this equity. For subscribers only.

Latest Press Releases

Bausch + Lomb Reports More Than Two Million Used Contact Lens Materials Recycled Through ONE by ONE Program
Canada Newswire - Thu Apr 19, 7:00AM CDT
Canada Newswire - CMTX
Thu Apr 19, 7:00AM CDT
Recycling Program Has Diverted More than 14,000 Pounds of Waste From Landfills
Valeant Announces Redemption of $150 Million Aggregate Principal Amount of Its Outstanding 6.375% Senior Unsecured Notes Due 2020
PR Newswire - Thu Apr 12, 3:15PM CDT
PR Newswire - CMTX
Thu Apr 12, 3:15PM CDT
Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) ("Valeant") today announced that Valeant Pharmaceuticals International, a wholly owned indirect subsidiary of Valeant, will redeem $150 million aggregate principal amount of its outstanding 6.375% Senior Unsecured Notes due 2020 (the "Notes"), using cash on hand, on May 14, 2018 and issued today an irrevocable notice of redemption for the Notes. The Notes were originally issued in 2012. Once the Notes have been redeemed, Valeant's total long-term debt will be approximately $25.4 billion.
Valeant Announces Redemption of $150 Million Aggregate Principal Amount of Its Outstanding 6.375% Senior Unsecured Notes Due 2020
PR Newswire - Thu Apr 12, 3:15PM CDT
PR Newswire - PRNW
Thu Apr 12, 3:15PM CDT
LAVAL, Quebec , April 12, 2018 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) ("Valeant") today announced that Valeant Pharmaceuticals International, a wholly owned indirect subsidiary of Valeant, will redeem $150 million aggregate principal amount of its outstanding 6.375% Senior Unsecured Notes due 2020 (the "Notes"), using cash on hand, on May 14, 2018 and issued today an irrevocable notice of redemption for the Notes. The Notes were originally issued in 2012. Once the Notes have been redeemed, Valeant's total long-term debt will be approximately $25.4 billion .
Price History Describes more index sector components

Price Performance

Period Period Low Period High Performance
1-Month 14.95 +14.88% increase
on 04/02/18
Period Open:15.98
Price movement based on the high, low and last over the given period.
17.72 -3.05% decrease
on 04/18/18
+1.20 (+7.51%) increase
since 03/20/18
3-Month 14.44 +18.98% increase
on 03/02/18
Period Open:21.52
Price movement based on the high, low and last over the given period.
22.86 -24.85% decrease
on 01/23/18
-4.34 (-20.17%) decrease
since 01/19/18
52-Week 8.31 +106.74% increase
on 04/24/17
Period Open:8.88
Price movement based on the high, low and last over the given period.
24.43 -29.68% decrease
on 01/05/18
+8.30 (+93.47%) increase
since 04/20/17

All market data is provided by Barchart Solutions (will open in new tab). Copyright © 2018.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

More stories below advertisement